RT Journal Article
SR Electronic
T1 Serum lysyl oxidase like-2 levels and idiopathic pulmonary fibrosis disease progression
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP erj01410-2013
DO 10.1183/09031936.00141013
A1 Jason W Chien
A1 Thomas J. Richards
A1 Kevin F. Gibson
A1 Yingze Zhang
A1 Kathleen O. Lindell
A1 Lixin Shao
A1 Susan K. Lyman
A1 Joanne I. Adamkewicz
A1 Victoria Smith
A1 Naftali Kaminski
A1 Thomas O'Riordan
YR 2013
UL http://erj.ersjournals.com/content/early/2013/10/30/09031936.00141013.abstract
AB We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes cross-linking of collagen in pathologic stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression (DP).Patients from ARTEMIS-IPF (n=69) and the Genomic and Proteomic Analysis of Disease Progression in IPF (GAP) study (n=104) were analysed. Baseline serum LOXL2 levels were compared to baseline clinical and physiologic surrogates of disease severity, and the association with IPF DP was assessed using a classification and regression tree (CART) method.sLOXL2 correlated weakly with forced vital capacity and carbon monoxide diffusion capacity (r range −0.24 to 0.05) in both cohorts. CART-determined thresholds were similar: ARTEMIS-IPF 800 pg·mL−1, GAP 700 pg·mL−1. In ARTEMIS-IPF, higher sLOXL2 (>800 pg·mL−1) was associated with increased risk for DP (hazard ratio [HR] 5.41, 95% confidence interval [CI] 1.65–17.73). Among GAP subjects with baseline spirometric data (n=70), higher sLOXL2 levels (>700 pg·mL−1) were associated with more DP events (HR 1.78, 95% CI 1.01–3.11). Among all GAP subjects, higher sLOXL2 levels were associated with increased risk for mortality (HR 2.28, 95% CI 1.18–4.38).These results suggest that higher sLOXL2 levels are associated with increased risk for IPF DP. However, due to multiple limitations, these results require validation.